Clinical Trials Logo
  1. Home
  2. Lung Cancer, Small Cell
  3. NCT00316186

First-line Treatment Of Subjects With Extensive Disease Small Cell Lung Cancer With Weekly Hycamtin And Paraplatin

Lung Cancer, Small Cell Clinical Trial

Official title:
An Open-label Phase II Study of Weekly Intravenous Hycamtin and Carboplatin as First-line Treatment of Chemonaive Subjects With Extensive Disease Small Cell Lung Cancer

Clinical Trial Summary

This study was designed to find the safest and most effective dose of a combination of two chemotherapy drugs, Hycamtin® (topotecan) and Paraplatin® (carboplatin), in people with extensive disease small cell lung cancer.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00316186
Study type Interventional
Source GlaxoSmithKline
Contact
Status Completed
Phase Phase 2
Start date June 2005
Completion date May 2009
View Details
See also
  Status Clinical Trial Phase
Completed NCT00046111 - A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With Advanced Solid Tumors Phase 1
Enrolling by invitation NCT06293833 - Implementation of Lung Cancer Screening in the First Line Zone of ZORA (Flanders), Using a Low Dose CT-scan N/A
Completed NCT00259935 - A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors Phase 1
Completed NCT01037023 - Regulatory Hycamtin(Oral) PMS N/A
Active, not recruiting NCT04986670 - NutriCare Plus a Medically Tailored Meal Intervention Among Patients With Lung Cancer N/A
Completed NCT00997061 - SCOT Registry: Small Cell Lung Cancer Treatment and Outcome N/A
Completed NCT00276276 - Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients With Relapsed Resistant Small Cell Lung Cancer Phase 3
Not yet recruiting NCT05320458 - Pulmonary Rehabılıtatıon Wıth Non-Small Lung Cancer N/A
Active, not recruiting NCT05228496 - A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC Phase 2
Not yet recruiting NCT04440800 - Feasibility of Wearable Activity Trackers for Detection of TOXicity in People Receiving Systemic Anticancer Treatment
Completed NCT00698516 - Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer Phase 2
Terminated NCT03499678 - Lung Cancer Screening Using DNA Methylation Changes in Circulated Tumor and PBMC DNA
Terminated NCT01313663 - A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population Phase 2
Active, not recruiting NCT04660929 - CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors Phase 1
Completed NCT00320359 - Topotecan Plus Cisplatin Versus Etoposide Plus Cisplatin In 1st Line Extensive Disease Small Cell Lung Cancer Phase 3
Completed NCT00043862 - The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC) Phase 2
Recruiting NCT06228326 - A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs Phase 1
Completed NCT04314895 - Trial of NanoPac Intratumoral Injection in Lung Cancer Phase 2